The first Cell and Gene Therapy Regulatory Report from Citeline and the International Society for Cell & Gene Therapy (ISCT) provides a global overview of the cell and gene therapy landscape, including pipeline, late-stage (Phase III and pre-registration), and approved products. It covers cell, genetically modified cell, and gene therapies.

Related resources

OCT 01, 2023

Gene, Cell, + RNA Therapy Landscape Q3 2023 Report

Q3 2023 saw 3,866 therapies in development; 53% of those were gene therapies, 25% RNA therapies, and 22% non-genetically modified cell therapies.

JUL 03, 2023

Quick Listen: Scrip's Five Must-know Things

Join us for an audio catch-up on the major events in the biopharma industry over the past business week.

DEC 01, 2022

In Vivo Outlook 2023

Outlook 2023 includes exclusive interviews and features on topics that reach across the life sciences.